ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Genetics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1659545
Predictive Value of Dual-Energy CT Assessment of Extracellular Volume Fraction on Efficacy of Immune Checkpoint Inhibitors in Patients with Liver Cancer
Provisionally accepted
- Affiliated Hospital of North Sichuan Medical College, Nanchong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the predictive value of dual-energy CT assessment of extracellular volume fraction (ECV) on the efficacy of immune checkpoint inhibitors (ICIs) in patients with liver cancer. Methods: A retrospective analysis was conducted on 179 liver cancer patients who received ICIs in our hospital between November 2023 and February 2025. Patients were divided into a group with excellent treatment efficacy (n=103) and a group with poor treatment efficacy (n=76). Univariate and binary Logistics regression analyses were performed to identify factors influencing treatment efficacy. The predictive value of ECV for the efficacy of ICIs in liver cancer patients was evaluated with receiver operating characteristic (ROC) curve analysis. Results: There were statistically significant differences in ECV, CRP, IL-6, NEU, and the status of other anti-tumor treatments between the two groups (P<0.05). Binary Logistics regression analysis indicated that ECV, CRP, IL-6, and NEU were factors influencing the efficacy of ICIs in liver cancer patients (P<0.05). ROC analysis showed that ECV had the highest area under the curve (AUC) of 0.839, with a standard error of 0.029 (95% CI: 0.781-0.896), a Youden index of 0.54, sensitivity of 56.58%, specificity of 97.09%, and an optimal cutoff value of 0.45. Patients were grouped based on the optimal critical value of ECV, with the survival probability of patients with ECV ≤ 0.45 being higher than that of patients with ECV > 0.45, showing statistically significant differences (P<0.05). Patients with ECV ≤ 0.45 also exhibited higher post-treatment immune function indicators compared to those with ECV > 0.45, with statistically significant differences (P<0.05). Conclusion: Dual-energy CT assessment of ECV demonstrates good predictive value in the efficacy of ICIs in liver cancer patients, assisting clinical judgment of treatment efficacy.
Keywords: Dual-energy CT, extracellular volume fraction, liver cancer, immune checkpoint inhibitors, Cancer
Received: 04 Jul 2025; Accepted: 13 Oct 2025.
Copyright: © 2025 Lei, Huang, Tang, Liu, Pan and Qianqian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiao-hua Huang, 15082797553@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.